Halozyme Therapeutics (HALO) Tops Q1 EPS by 4c; FY Revenue Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.34 +1.34%
Revenue Growth %: +37.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +37.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.16), $0.04 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $42.5 million versus the consensus estimate of $29.65 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $130-145 million, versus the consensus of $127.89 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MKS Instruments (MKSI) Tops Q3 EPS by 55c, Beats on Revenue; Offers Q4 Guidance
- PROCEPT BioRobotics Corporation (PRCT) Misses Q3 EPS by 7c
- Onterris, Inc. (ONT) Tops Q3 EPS by 48c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
